Animal Model Market Set to Surpass USD 5.81 Billion by 2034

The global animal model market is valued at USD 2.54 billion in 2024, with an increase to USD 2.76 billion in 2025. By 2034, the market is expected to reach approximately USD 5.81 billion, growing at an annual rate of 8.64% from 2025 to 2034. This growth is driven by the rising research and development activities, the growing prevalence of chronic diseases, and increased investments in the field.

Download Statistical Data: https://www.towardshealthcare.com/download-statistics/5390

Animal Model Market: Investigating Non-Human Species in Biomedical Research

In the world of biomedical research, animal models play a pivotal role in advancing our understanding of human diseases and testing potential treatments. These non-human species are invaluable in mimicking the biological processes and diseases found in humans, providing researchers with essential insights into conditions that may be too difficult or unethical to explore in human trials. By simulating the structural and functional aspects of human biology, animal models have become a cornerstone in the search for innovative medical solutions.

The Importance of Animal Models in Research

Animal models, which include species such as mice, rats, guinea pigs, zebrafish, monkeys, and dogs, are crucial for studying the mechanisms of diseases, testing new drugs, and investigating the safety and efficacy of treatments. These models are selected based on their biological similarity to humans, allowing researchers to gain a deeper understanding of how human diseases develop and respond to treatments. Animal models are especially vital in cases where human experimentation would be unfeasible or unethical. By using animals with similar genetic and physiological characteristics to humans, scientists can explore the potential of new drugs and therapies in a controlled and ethically responsible environment.

The growing global incidence of chronic diseases, particularly among the aging population, is a driving force behind the increasing demand for animal models in medical research. As the number of elderly individuals continues to rise, there is a heightened need for innovative treatments to address conditions like diabetes, cardiovascular diseases, cancer, and neurodegenerative disorders. Consequently, pharmaceutical companies and research institutions are intensifying their research efforts, which directly contributes to the expansion of the animal model market.

A Shifting Landscape in Biomedical Research

The landscape of animal model research has evolved significantly in recent years, driven by advancements in technology, regulatory changes, and a growing emphasis on precision medicine. In particular, the demand for preclinical testing has skyrocketed, as regulatory bodies worldwide now require comprehensive preclinical study data before allowing human clinical trials. This growing regulatory emphasis ensures that treatments undergo rigorous testing in animals, further expanding the role of animal models in the development of new therapies.

In addition to regulatory frameworks, increased investments and collaborations among pharmaceutical companies, biotechnology firms, and research organizations have further propelled the growth of the animal model market. Such collaborations often aim to streamline research and accelerate the development of novel products, particularly in areas where there is an urgent need for innovative treatments.

Notable Developments in the Animal Model Market

Several recent milestones highlight the significant strides being made in the animal model market:

• October 2024: Researchers from the La Jolla Institute for Immunology (LJI) unveiled six new lines of humanized mice, designed to serve as valuable models for studying human COVID-19 cases. These specially engineered mouse models incorporate human molecules crucial to the infection process, enabling more accurate simulations of the disease in humans.

• September 2024: Nimmune Biopharma entered into a strategic collaboration with BioTherapeutics, Inc. to accelerate the development of new products. This partnership will provide access to BioTherapeutics' preclinical services and regulatory expertise, enhancing the use of animal and computational models to support the development of precision immunology treatments.

• June 2024: Biosplice Therapeutics, Inc. announced a partnership with Novo Nordisk to explore new drug candidates for diabetes. This collaboration is expected to push the boundaries of diabetes research, with animal models playing a central role in the preclinical phase.

These developments reflect the dynamic and fast-paced growth of the animal model market, driven by cutting-edge research, strong collaborations, and the increasing need for innovative medical treatments.

The Role of AI in Revolutionizing Animal Model Research

One of the most exciting innovations in the animal model market is the integration of artificial intelligence (AI) and machine learning (ML) technologies. AI and ML are transforming how animal models are selected, tested, and analyzed, providing researchers with powerful tools to optimize preclinical studies and improve the reliability of results.

AI and ML can assist in the selection of the most appropriate animal models for specific experiments, ensuring that the chosen species accurately represents human disease processes. By analyzing vast amounts of data from diverse sources, AI and ML algorithms can extract meaningful insights that would otherwise be difficult to identify using traditional methods.

Additionally, AI can optimize experimental design by automating tasks such as dose calculations and dose delivery to animal models. With precise control over dosage, researchers can ensure more accurate and consistent results. Furthermore, AI and ML technologies can notify researchers of the ideal time for dose administration, enhancing the efficiency and reliability of preclinical testing.

Another crucial benefit of AI and ML is their ability to predict how animal models will respond to treatments. By analyzing patterns in data, these technologies can anticipate the outcomes of specific interventions, allowing researchers to refine their experimental approaches and improve the translation of animal model results to human clinical trials.

Moreover, the combination of AI and ML analysis of animal model data with human clinical data holds immense potential for accelerating the development of human therapies. By aligning animal model research with clinical findings, AI and ML enable a more seamless transition from preclinical studies to human trials, improving the relevance and accuracy of findings. This could ultimately lead to faster drug development and more effective treatments for a wide range of diseases.

Future Outlook for the Animal Model Market

As the demand for more accurate and efficient drug development continues to grow, the role of animal models in biomedical research will remain central to the advancement of healthcare. With the support of emerging technologies like AI and ML, the future of animal model research looks promising, with the potential to significantly enhance the efficacy of preclinical studies and the success rate of clinical trials.

The integration of AI-driven innovations into the animal model market will not only increase the precision of research but also pave the way for personalized medicine approaches, where treatments are tailored to individual patients based on genetic and biological factors. This personalized approach to medicine, supported by advanced animal models, will help address the challenges of complex diseases and ultimately improve patient outcomes.

As the market for animal models continues to expand, driven by technological advancements, increasing regulatory requirements, and the ever-growing need for novel treatments, the future of biomedical research is more promising than ever. Researchers, pharmaceutical companies, and regulatory bodies must continue to collaborate and innovate, ensuring that animal models remain a critical tool in the development of safer and more effective therapies for human diseases.

The Growth and Challenges of the Animal Model Market: An In-Depth Analysis
The global animal model market is witnessing remarkable growth, fueled by the increasing demand for research and development (R&D) in the pharmaceutical and biotechnology sectors. Animal models have become a cornerstone in understanding disease progression, drug development, and the safety of new treatments. They are also vital tools in various other research domains, from tissue engineering to medical device development. However, while the market is flourishing, it also faces significant challenges, including ethical concerns and the development of alternative testing methods. Despite these obstacles, opportunities continue to emerge, especially with the rising demand for regenerative medicine.

Drivers of Market Growth

One of the most significant factors driving the growth of the animal model market is the surge in R&D activities across various scientific disciplines. Animal models play a pivotal role in preclinical studies, where they help assess the safety, efficacy, and toxicity of drugs and medical devices before clinical trials. In particular, they are indispensable for testing novel drug delivery systems and evaluating the effectiveness of treatments for chronic conditions such as rheumatoid arthritis, Alzheimer's disease, cancer, and cardiovascular diseases. The need to better understand these complex diseases propels the demand for animal models, which are used extensively in both drug development and the advancement of medical technologies.

Moreover, the government's support for R&D initiatives, alongside substantial investments in research laboratories, continues to foster market growth. Policies designed to encourage innovation in biotechnology and pharmaceuticals further boost the adoption of animal models. As the global healthcare industry continues to grapple with the increasing burden of chronic diseases, the demand for animal models to study disease mechanisms and develop targeted therapies is expected to rise sharply.

Restraints: Ethical Issues and the Rise of Alternatives

Despite the growing demand for animal models, the market faces significant restraints, particularly in the form of ethical concerns. Animal testing has long been a controversial topic due to the ethical implications of using animals for research purposes. To address these concerns, governments and regulatory bodies have introduced guidelines to reduce animal usage and minimize suffering. Public perception of animal testing also plays a crucial role in shaping the future of this market. As societal attitudes evolve, there is growing pressure to find alternatives to animal testing that align with ethical standards.

Additionally, advancements in alternative methods, such as organs-on-chips and 3D cell culture models, pose a growing threat to the animal model market. These technologies offer a potential replacement for animal testing by simulating human biology more accurately. The rapid development of such alternatives could slow the adoption of animal models, especially in areas where these new technologies prove to be more effective or less controversial.

Opportunities in Regenerative Medicine

One of the most promising opportunities for the animal model market lies in the burgeoning field of regenerative medicine. This innovative branch of medicine focuses on using biological materials to regenerate damaged tissues or organs, offering potential treatments for a wide range of disorders, including musculoskeletal, neurological, and autoimmune diseases. Animal models are crucial in this research to test the safety, efficacy, and dosage of regenerative therapies, particularly in stem cell research.

Large animal models such as rabbits, dogs, and sheep are often preferred in regenerative medicine studies due to their closer physiological similarities to humans compared to smaller animals like rodents. As the demand for regenerative medicines grows, the need for animal models to facilitate their development is expected to drive market expansion. Moreover, government policies supporting stem cell research and the launch of new regenerative therapies provide a favorable environment for the market's growth.

Mice: Dominating the Market in 2024

In 2024, the mice segment accounted for the largest share of the animal model market. Mice are widely used in research due to their genetic, anatomical, and physiological similarities to humans. Their short lifespan of 2 to 3 years makes them ideal for studying the progression of diseases over time. Additionally, mice are relatively easy to breed and maintain, making them a cost-effective option for researchers. Their ability to be genetically modified to simulate human diseases adds to their popularity in scientific studies. This ability to study genetic predispositions and disease mechanisms makes mice an indispensable tool in biomedical research, further solidifying their dominance in the market.

Guinea Pigs: A Growing Segment

The guinea pig segment is expected to experience significant growth in the coming years. Known for their biological similarities to humans, guinea pigs are particularly valuable in the study of respiratory diseases, allergies, and nutritional research. Their sensitivity to allergens makes them an ideal model for asthma research, and they are also used in hearing studies and safety testing. With their growing application in immunological research and other fields, guinea pigs are gaining traction as a reliable animal model, contributing to the expansion of this market segment.

Cancer Research: The Largest Application Segment

The cancer research application segment holds the largest share of the animal model market in 2024. With the rising prevalence of cancer worldwide, there is a significant demand for animal models to study tumor behavior, test potential treatments, and understand the molecular mechanisms underlying cancer progression. Mice, rats, and other animals are commonly used in cancer research to mimic human disease, evaluate therapeutic responses, and study cancer genomics. Animal models are also used in the development of new cancer therapies, including immunotherapies and targeted treatments, further driving the growth of this segment.

Immunological Diseases: A Rapidly Growing Segment

Among the various applications of animal models, immunological diseases are expected to be the fastest-growing segment in the coming years. Autoimmune disorders, in particular, are on the rise, with a growing number of individuals affected by conditions such as rheumatoid arthritis, lupus, and multiple sclerosis. Animal models play a crucial role in studying the mechanisms of autoimmune diseases and developing treatments. Mice, guinea pigs, and monkeys are frequently used in research to model human autoimmune conditions, providing insights into disease progression and potential therapeutic approaches.

Pharmaceutical & Biotechnology Companies: The Market Leaders

Pharmaceutical and biotechnology companies were the dominant end-users of animal models in 2024. The extensive use of animal models in drug discovery, toxicity testing, and preclinical research explains the leading position of this segment. Companies such as Merck & Co., Roche, and Johnson & Johnson, which have some of the highest R&D expenditures, are significant contributors to the market's growth. The demand for animal models in pharmaceutical R&D is further fueled by the rising costs of drug development, with new therapies requiring more extensive testing before reaching clinical trials.

Contract Research Organizations: The Fastest-Growing End-User Segment

Contract Research Organizations (CROs) represent the fastest-growing end-user segment in the animal model market. CROs provide outsourced research services for pharmaceutical and biotechnology companies, enabling them to reduce costs and improve efficiency in drug development. With the increasing need for new medicines, especially for rare diseases, the demand for CROs to conduct preclinical trials is growing rapidly. These organizations offer specialized facilities and expert researchers, making them an attractive option for companies looking to streamline their R&D processes.

Animal Model Market: Regional Insights and Industry Developments in 2024
The global animal model market has witnessed substantial growth, with regions such as North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa contributing significantly to its expansion. In 2024, North America maintained its leadership position, driven by stringent regulatory policies, advanced research and development infrastructure, and the presence of key market players. Meanwhile, Asia-Pacific is expected to experience the highest compound annual growth rate (CAGR) due to increasing investments, expanding pharmaceutical sectors, and collaborative initiatives that enhance research and development in the region.

North America: Dominating the Market with Stringent Regulatory Frameworks
In 2024, North America continued to dominate the animal model market, accounting for a substantial share of global usage. The region's dominance is fueled by the rising incidences of chronic diseases, cutting-edge research and development (R&D) facilities, and the influence of regulatory agencies, such as the U.S. Food and Drug Administration (FDA). These regulations, particularly the Animal Rule, have played a pivotal role in the approval process for new drugs, requiring animal studies to provide vital evidence of effectiveness.

The FDA's strict regulatory policies, such as the Animal Rule, mandate that animal models must demonstrate the safety and effectiveness of drugs before they can receive marketing approval. This rule is integral to the approval process for drugs related to public health emergencies, such as the COVID-19 pandemic. In the U.S., rats and mice remain the most commonly used animal models in research, representing 95% of all warm-blooded animals used. Non-human primates, while crucial for certain types of research, account for less than 1% of the total warm-blooded laboratory animals.

In Canada, the composition of animals used for research in 2024 reflects a similar trend. Mice are the most frequently used animals (36.8%), followed by fish (32.2%) and cattle (17.5%). The well-established infrastructure and regulatory frameworks in North America ensure a steady demand for animal models, securing the region's position as a leader in the global market.

Asia-Pacific: A Region Poised for Growth with Expanding R&D and Investments
While North America leads in market share, Asia-Pacific is poised to experience the highest growth in the coming years. A combination of growing research initiatives, increasing investments, and a thriving pharmaceutical sector positions this region as a major player in the animal model market.

Several government initiatives are contributing to the region's rapid growth. In Japan, the government launched the "Strengthening Drug Discovery Venture Ecosystem Project," with a budget of 300 billion yen starting in 2022. This project is designed to bolster pharmaceutical research and foster collaborations between academia and industry. Similarly, in India, the "Scheme for Promotion of Research & Innovation in Pharma Sector (PRIP)" was introduced with an allocated budget of Rs. 5,000 crore for the years 2024 to 2027. Such initiatives underscore the growing importance of animal models in the advancement of pharmaceutical research.

China and India, two of the largest pharmaceutical markets in Asia-Pacific, also play a significant role in driving the demand for animal models. With over 10,000 major pharmaceutical firms in China and around 3,000 in India, the need for animal models to support drug development and clinical trials is greater than ever.

Key Companies in the Animal Model Market: A Snapshot of the Industry Leaders

The animal model market is highly competitive, with a number of global companies playing a crucial role in advancing the field. Leading companies in the market include:

• Altogen Labs
• Animal Biotech Industries
• Biocytogen Pharmaceuticals Co. Ltd.
• Charles River Laboratories
• Cyagen
• Genoway
• Hera BioLabs
• Horizon Discovery
• Inotiv
• Janvier Labs
• Ozgene Pvt. Ltd.
• Taconic Biosciences
• The Jackson Laboratory
• Trans Genic, Inc.
• Transposagen Biopharmaceuticals

These companies are constantly innovating, providing cutting-edge animal models for research, and enhancing the development of new therapeutic solutions. Their contributions are critical in supporting the ongoing growth of the market.

Recent Announcements and Industry Developments

• The industry has seen numerous advancements in recent months, showcasing the critical role that animal models play in the development of new medical treatments. In a notable announcement, Dr. Sujan Shresta, Ph.D., LJI Professor, discussed the development of a novel mouse model to study SARS-CoV-2 infection and vaccination settings. While acknowledging that no animal model can perfectly replicate human disease, Dr. Shresta emphasized the goal of creating a model that closely mimics human disease and immune responses, contributing to pandemic preparedness efforts globally.

• Another significant development in the animal model market occurred in November 2024 when researchers from MedUni Vienna investigated a novel active substance, AC102, for treating acute sudden hearing loss. Promising results from animal models suggest a breakthrough in the treatment of acute hearing disorders, potentially transforming the therapeutic approach to these conditions.

• In July 2024, researchers from The University of Texas Health Science Center developed a humanized mouse model with a human immune system and a human-like gut microbiome. This innovative model can now mount specific antibodies, enhancing the precision of drug testing and offering valuable insights into human diseases and treatments.

Source: https://www.towardshealthcare.com/insights/animal-model-market-sizing

Baner

Buy Premium Global Insight: https://www.towardshealthcare.com/price/5390

Review the Full TOC for the Animal Model Market Report: https://www.towardshealthcare.com/table-of-content/animal-model-market-sizing

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

We've prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

This release was published on openPR.